欢迎访问《岭南现代临床外科》官方网站,今天是

岭南现代临床外科 ›› 2016, Vol. 16 ›› Issue (06): 647-651.DOI: 10.3969/j.issn.1009-976X.2016.06.003

• 论著与临床研究 • 上一篇    下一篇

环孢素A在透明质酸诱导大鼠间质性膀胱炎/膀胱疼痛综合征中的治疗作用

谢伟杰 徐曦 张嘉鹏 姚友生   

  1. 中山大学孙逸仙纪念医院
  • 通讯作者: 谢伟杰
  • 基金资助:

    拟真PBS/IC大鼠模型的构建及PGE2在其炎症疼痛发展中的作用和机制;拟真PBS/IC大鼠模型的构建及IL17阳性T细胞在其炎症发展中的作用和机制研究

Therapeutic effect of cyclosporin A on hyaluronidase induced interstitial cystitis/bladder pain sydrome (IC/BPS) in rats.

XIE Weijie,XU Xi,ZHANG Jiapeng,YAO Yousheng   

  1. Department of Urology,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China.
  • Online:2016-12-20 Published:2016-12-20

摘要:

目的 观察环孢素A(CsA)在透明质酸酶诱导的大鼠间质性膀胱炎/膀胱疼痛综合征(IC/BPS)中的治疗作用。方法 将45只成年雌性Sprague-Dawley(SD)大鼠(200~250 g),分为对照组15只(膀胱灌注生理盐水),模型组15只(膀胱灌注透明质酸酶),CsA治疗组15只(膀胱灌注透明质酸酶+CsA)。采用长期(1个月)间歇灌注透明质酸酶(4 g/L)构建大鼠IC/BPS模型,尿流动力学检测膀胱功能,VonFrey刷检测泌尿生殖区疼痛变化,硝酸还原酶法测定膀胱组织NO的含量,逆转录聚合酶链反应(RT-PCR)检测iNOS、IL-6、IL-10及IL-17 mRNA表达,ELISA法检测膀胱组织IL-6、IL-10及IL-17含量。结果 与对照组相比,模型组膀胱大鼠膀胱iNOS、IL-6、IL-10、IL-17 mRNA表达均显著升高(P<0.001),在予以CsA治疗后,其mRNA表达均显著下调(P<0.05)。模型组膀胱NO含量为9.73±2.62 μmol/g;IL-6含量为125.4±11.25 μg/g;IL-10含量为64.05±6.26 μg/g;IL-17含量为90.61±10.49 μg/g;排尿时间间隔为148.23±40.75 s;膀胱容量为0.41±0.06 mL。对照组膀胱NO含量为1.31±0.55 μmol/g;IL-6含量为55.18±5.07 μg/g;IL-10含量为32.12±3.82 μg/g;IL-17含量为44.45±4.92 μg/g;排尿时间间隔为441.90±34.96 s;膀胱容量为1.27±0.10 mL。与对照组比较,模型组大鼠膀胱NO、IL-6、IL-10、IL-17含量均明显升高,排尿时间间隔缩短,膀胱容量降低,疼痛评分显著增加(P<0.05)。与模型组相比,CsA治疗组大鼠的膀胱组织NO、IL-6、IL-10、IL-17含量均显著减少(P<0.001),分别为3.97±1.71 μmol/g;62.29±6.68 μg/g;33.51±5.77 μg/g;51.88±6.67 μg/g,排尿时间间隔及膀胱容量明显增加(P<0.05),分别为422.06±42.22 s、1.14±0.15 mL,疼痛评分也明显下调(P<0.05)。结论 在透明质酸酶诱导的IC/BPS大鼠模型中,CsA膀胱灌注治疗能显著改善大鼠的尿流动力学及疼痛症状,这可能与其下调iNOS、NO、IL-6、IL-10及IL-17等炎症介质的表达有关。

关键词: 膀胱疼痛综合征, 炎症介质, 环孢素 A, 间质性膀胱炎

Abstract:

Objective To evaluate the therapeutic effect of cyclosporin A (CsA) on hyaluronidase induced interstitial cystitis/bladder pain sydrome (IC/BPS) in rats. Methods Forty-five Sprague-Dawley rats were randomly divided into control group (15 rats, intravesical normal saline), model group(15 rats, intravesical hyaluronidase) and CsA-treated group (15 rats, intravesical hyaluronidase+CsA). Voiding patterms were investigated by cystometrography. The changes of pain in urogenital area were detected by Von-Frey Hairs. The NO level of bladder tissue were measured by using nitric acid deoxidize enzyme method. The mRNA 1evels of iNOS, IL-6, IL-10, IL-17 were analyzed with real time reverse transcription polymerase chain reaction. The IL-6, IL-10 and IL-17 level were measured by ELISA. Results Compared with control, the mRNA level of iNOS, IL-6, IL-10, IL-17 increased significantly (all P values<0.001). The CsA-treated group showed decreased mRNA levels of iNOS, IL-6, IL-10, IL-17 (all P values<0.05). In model group, the NO level was (9.73±2.62)μmol/g; the IL-6 level was (125.4±11.25) μg/g;the IL-10 level was(64.05±6.26)μg/g;the IL-17 level was(90.61±10.49)μg/g. The intercontraction intervals was(148.23±40.75)s; The bladder capacity was 0.41±0.06 m1. In control group, the NO level was 1.31±0.55 μmol/g; the IL-6 level was 55.18±5.07 μg/g. The IL-10 level was(32.12±3.82)μg/g; the IL-17 level was(44.45±4.92)μg/g. The intercontraction intervals was 441.90±34.96 s; The bladder capacity was 1.27±0.10 m1. Compared with control, the rats of model group showed high NO, IL-6, IL-10 and IL-17 level, decreased intercontraction intervals and bladder capacity, high pain score (all P<0.05). After administration of CsA, the NO, IL-6, IL-10 and IL-17 level of bladder reduced (P<0.001), which was 3.97±1.71 μmol/g, 62.29±6.68 μg/g, 33.51±5.77 μg/g and 51.88±6.67 μg/g, respectively. Both intercontraction intervals and bladder capacity increased significantly (both P<0.05). And they were 422.06±42.22 s and 1.14±0.15 ml, respectively. The pain score also decreased significantly (P<0.05). Conclusion In the IC/BPS rat model induced by hyaluronidase, intravesical CsA can significantly ameliorate the frequent urination and bladder pain, which may be related to the down-regulation of iNOS, NO, IL-6, IL-10 and IL-17.

Key words: Interstitial cystitis, Inflammation mediator, Bladder pain syndrome, Cyclosporin A

中图分类号: